Search Results

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.cslseqirus.ca/news/news-archives

Seqirus Ready to Reinforce Canada’s Influenza Pandemic Preparedness Plans

https://www.cslseqirus.ca/news/news-archives/seqirus-ready-to-reinforce-canadas--influenza-pandemic-preparedness-plans

CSL Seqirus Commends the National Advisory Committee on Immunization for Preferential Recommendation of Enhanced Influenza Vaccines for Adults 65 and Older

https://www.cslseqirus.ca/news/seqirus-commends-naci-for-preferential-influenza-for-adults-65-and-older

Despite high burden of disease, influenza continues to suffer from perceived lack of risk, contributing to low vaccine uptake among parents and Canadian adults

https://www.cslseqirus.ca/news/news-archives/canadian-surveys-highlight-flu-ed-with-healthcare-pros-ease-of-access-critical-vaccination-uptake

The Government of British Columbia has recently announced that this season they will publicly fund FLUAD®, an inactivated, adjuvanted seasonal influenza vaccine indicated for all seniors residing in a community setting.

https://www.cslseqirus.ca/news/news-archives/csl-seqirus-ca-gov-of-brit-columbias-decision-make-fluad-publicly-avail-all-brit-columbian-seniors

Seqirus Receives Health Canada Approval for Expanded Age Indication of Its Cell-Based Quadrivalent Influenza Vaccine for People as Young as Six Months

https://www.cslseqirus.ca/news/news-archives/seqirus-receives-health-canada-approval-for-expanded-age-indication-for-people-as-young-as-6-months

NEJM study indicates that the seasonal influenza vaccine was effective and produced a sufficient immune response against influenza in children and adolescents ≥2 to <18 years of age

https://www.cslseqirus.ca/news/news-archives/nejm-study-cell-based-quadrivalent-influenza-vaccine-efficacy-in-children

Seqirus Presents Key Insights on Influenza Vaccines at the Canadian Immunization Conference 2020

https://www.cslseqirus.ca/news/news-archives/seqirus-presents-key-insights-on-influenza-vaccines

Seqirus Announces Health Canada Approval of Expanded Age Indication

https://www.cslseqirus.ca/news/news-archives/seqirus-announces-health-canada-approval-of-expanded-age-indication

Seqirus announces Health Canada approval of first cell-based seasonal influenza vaccine

https://www.cslseqirus.ca/news/news-archives/seqirus-announces-health-canada-approval-of--first-cell-based-seasonal-influenza-vaccine